Company intelligence

EQ

Equillium, Inc. · NASDAQ · Healthcare

Price$1.45+2.84% · +$0.04

Market cap91.68MEquity value

P / E-7.3Trailing ratio

Volume793.19KLatest session

Market data

EQ price chart

TradingView

Related signals

1 min delayed

Browse public EQ signals with their source context and measured market impact. Open any signal for its permanent analysis page.

EQMar 27, 2025-21.27% since signal

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Equillium's Phase 3 study showed itolizumab did not meet early efficacy benchmarks. Long-term outcomes show significant benefits for itolizumab in aGVHD treatment. Equillium plans to seek Accelerated FDA Approval based on study results. Itolizumab demonstrates favorable safety without increasing serious infection risks. EQ shares fell 33.3%, reflecting market skepticism post-study data release.

View signal analysis

EQMay 9, 2024-15.00% since signal

Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates

- Equillium, Inc. reported a quarterly loss of $0.08 per share, beating estimates. - Revenue for Equillium was $10.69 million, surpassing expectations by 16.82%. - Equillium shares have risen 135.1% this year, outperforming the S&P 500. - Price Impact Rating: Bullish - Impact Horizon Rating: Short-term - Type: Earnings

View signal analysis

Research